AK 1

Drug Profile

AK 1

Alternative Names: Actokine-1; AK1

Latest Information Update: 20 May 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ActoKine Therapeutics
  • Class Antineoplastics; Chemoprotectants; Cytokines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Chemotherapy-induced damage; Radiation injuries

Most Recent Events

  • 20 May 2010 Preclinical development is ongoing in USA
  • 01 Jun 2006 This compound is still in active development
  • 13 May 2003 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top